Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 10;6(4):otae055.
doi: 10.1093/crocol/otae055. eCollection 2024 Oct.

Clinical Approach to STRIDE-II in Real-Life Settings: Analysis and Practical Recommendations

Elena Ricart  1 , Guillermo Bastida  2 , Daniel Carpio  3 , Daniel Ceballos  4 , Daniel Ginard  5 , Ignacio Marín-Jimenéz  6 , Luis Menchén  6 , Fernando Muñoz  7 , Yago González-Lama  8
Affiliations

Clinical Approach to STRIDE-II in Real-Life Settings: Analysis and Practical Recommendations

Elena Ricart et al. Crohns Colitis 360. .

Abstract

Background: We aimed to (1) analyze the applicability of the updated Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE-II) recommendations in real-world clinical practice, (2) identify barriers to their implementation, and (3) propose practical measures to overcome these obstacles.

Methods: This qualitative study was based on a survey, a literature review, and expert opinions. Nine inflammatory bowel disease (IBD) experts identified 7 areas likely to be controversial or potential implementation barriers in daily clinical practice: endoscopy, histology, ultrasound, quality of life, biomarkers, symptom control, and patient-reported outcomes (PROs). Based on this, a survey was carried out among educational course participants. The experts discussed the literature review and survey results and proposed several statements and practical actions.

Results: A total of 55 gastroenterologists answered the survey. The reported difficulty level in reaching STRIDE-II treatment goals in clinical practice was high. Only 22% of participants performed clinical remission assessments using clinical indexes and PROs. Seventy percent of responders did not use fecal calprotectin cutoffs and considered changes from the previous levels instead. Mucosal healing as a long-term therapeutic goal was considered necessary to be individualized in specific patient subgroups (eg, elderly/fragile patients, multiple treatment failures, and last-line therapies). Other barriers, like the lack of access to imaging techniques or insufficient knowledge and skills among healthcare professionals, were detected. The experts suggested adding less stringent treatment goals and measurements, patient stratification, local adaptations, educational activities, and research.

Conclusions: STRIDE-II recommendations face various implementation barriers needing careful evaluation in order to enhance their adoption in clinical practice, and ultimately improve outcomes in IBD patients.

Keywords: Crohn’s disease; expert opinions; implementation; inflammatory bowel disease; ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

ER has received support for congress and conference attendance, speaker fees, research support, or consulting fees from MSD, Abbvie, Ferring, Janssen, Otsuka, Pfizer, Takeda, Faes Farma, Galapagos, Kern Pharma, Lilly, and Fresenius-Kabi. DG has received support for congress and conference attendance, speaker fees, or consulting fees from MSD, Abbvie, Ferring, Janssen, Adacyte, Pfizer, Takeda, Faes Farma, Galapagos, Kern Pharma, Lilly, and Fresenius-Kabi. I M-J has been a speaker, consultant, and advisory member for or has received research funding from Abbvie, Amgen, Chiesi, Dr. Falk Pharma, Faes Farma, Ferring, Fresenius, Galapagos, Gebro Pharma, Janssen, Kern Pharma, Lilly, MSD, Otsuka Pharmaceutical, Pfizer, Sandoz, Shire Pharmaceuticals, Takeda, Tillotts Pharma, and Vifor Pharma. LM has been a speaker, consultant, or advisory member for or has received unrestricted grants from MSD, Abbvie, Takeda, Janssen, Pfizer, Biogen, Galapagos, Kern Pharma, Lilly Otsuka Pharmaceuticals, Tillotts, Dr. Falk Pharma, Ferring, Medtronic, and General Electric. DC has been a speaker, consultant, or advisory member for or has received unrestricted grants from Abbvie, Dr Falk Pharma, Faes, Ferring, Galapagos, Johnson & Johnson, Kern Pharma, Lilly, MSD, Pfizer, Takeda, and Tillots. The rest of the authors declare no conflicts of interest.

Figures

Graphical Abstract
Graphical Abstract
See this image and copyright information in PMC

References

    1. Alabat S, Sepanlou SG, Ikuta K, et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(1):17-30. doi:10.1016/s2468-1253(19)30333-4. (In Eng). - DOI - PMC - PubMed
    1. Bernabeu P, Belén-Galipienso O, van-der Hofstadt C, et al.Psychological burden and quality of life in newly diagnosed inflammatory bowel disease patients. Front Psychol. 2024;15:1334308. doi:10.3389/fpsyg.2024.1334308. (In eng). - DOI - PMC - PubMed
    1. Saleh A, Abraham BP.. Utility of intestinal ultrasound in clinical decision-making for inflammatory bowel disease. Crohns Colitis 360. 2023;5(3):otad027. doi:10.1093/crocol/otad027. (In eng) - DOI - PMC - PubMed
    1. Ashraf H, Bodapati A, Hanif A, et al.Safety and efficacy of biologic therapies (ustekinumab and vedolizumab) in the treatment of Inflammatory Bowel Disease (IBD): a systematic review. Cureus. 2023;15(11):e48338. doi:10.7759/cureus.48338. (In eng) - DOI - PMC - PubMed
    1. Solitano V, Vuyyuru SK, MacDonald JK, et al.Efficacy and safety of advanced oral small molecules for inflammatory bowel disease: systematic review and meta-analysis. J Crohns Colitis. 2023;17(11):1800-1816. doi:10.1093/ecco-jcc/jjad100. (In eng) - DOI - PubMed

LinkOut - more resources